Recently, the first fluorescent quantitative detection kit for serum HBV pregenomic RNA, jointly developed by Professor Lu Fengmin Research Team from Peking University School of Basic Medical Sciences and Beijing Hotgen Biotech Co., Ltd., was approved by National Medical Products Administration. This means that the new target, which can be used as a guide for safe drug withdrawal of chronic hepatitis B patients, will officially enter clinical application and can be tested in hospitals at all levels. This kit is one of the important achievements of the "Major Projects for Infectious Disease Prevention and Control" of the National Medium and Long-term Science and Technology Development Plan.

　　Lu Fengmin said that the approved fluorescent quantitative detection kit for serum hepatitis B virus pregenomic RNA has high detection sensitivity, specificity and stability, can be widely used in clinical practice, can provide important evidence for drug use monitoring of chronic hepatitis B patients, and is expected to improve the precise management of antiviral treatment for chronic hepatitis B patients, so that more chronic hepatitis B patients who receive nucleoside (acid) drugs can stop taking drugs safely and avoid the pain of lifelong medication.

　　Written by: Wu Zhaoxia

　　Edited by:Liu Xin

　　Source: School of Basic Medical Sciences